Current Treatment for Restless Legs Syndrome

Arthur Walters, Wayne Hening, Richard Allen

Research output: Contribution to journalArticle

Abstract

Medication treatment for restless legs syndrome (RLS) began with the opioids, which were first introduced as treatment in the 17th century and are still used today. Then came the benzodiazepines, the first “modern” treatment for RLS. Today, Sinemet and the dopamine agonists are first-line treatments—their efficacy make them the most commonly used medications. The benzodiazepines are effective for mild cases of RLS, but are not typically used as a monotherapy and often necessitate combination with the opioids or a dopamine agonist. The opioids can be used in a number of clinical settings, and studies are being conducted to test their efficacy as a long-term monotherapy for certain patients. The advent of dopamine agents, particularly Sinemet, has revolutionized RLS treatments. Studies show 90–100% initial efficacy. However, continued use of Sinemet can produce augmentation of a patient's symptoms. To combat augmentation a dopamine agonist like Permax is typically introduced, which has a much lower incidence of augmentation, but which must be built up slowly to enhance tolerability. Two new dopamine agonists, Mirapex and Requip, demonstrate therapeutic benefits but are not efficacious enough to replace the tested agonists. While treatment of RLS has greatly improved over the history of the disorder, the search still continues for a single therapy that can effectively treat RLS patients over the long term without fear of augmentation and undesirable side effects.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCNS Spectrums
Volume4
Issue numberS2
DOIs
StatePublished - 1999

Fingerprint

Restless Legs Syndrome
Dopamine Agonists
Opioid Analgesics
Benzodiazepines
Therapeutics
Pergolide
Dopamine Agents
Fear
History
Incidence

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Current Treatment for Restless Legs Syndrome. / Walters, Arthur; Hening, Wayne; Allen, Richard.

In: CNS Spectrums, Vol. 4, No. S2, 1999, p. 1-7.

Research output: Contribution to journalArticle

Walters, Arthur ; Hening, Wayne ; Allen, Richard. / Current Treatment for Restless Legs Syndrome. In: CNS Spectrums. 1999 ; Vol. 4, No. S2. pp. 1-7.
@article{3f04be3399a7447681d32c6f4e033ef3,
title = "Current Treatment for Restless Legs Syndrome",
abstract = "Medication treatment for restless legs syndrome (RLS) began with the opioids, which were first introduced as treatment in the 17th century and are still used today. Then came the benzodiazepines, the first “modern” treatment for RLS. Today, Sinemet and the dopamine agonists are first-line treatments—their efficacy make them the most commonly used medications. The benzodiazepines are effective for mild cases of RLS, but are not typically used as a monotherapy and often necessitate combination with the opioids or a dopamine agonist. The opioids can be used in a number of clinical settings, and studies are being conducted to test their efficacy as a long-term monotherapy for certain patients. The advent of dopamine agents, particularly Sinemet, has revolutionized RLS treatments. Studies show 90–100{\%} initial efficacy. However, continued use of Sinemet can produce augmentation of a patient's symptoms. To combat augmentation a dopamine agonist like Permax is typically introduced, which has a much lower incidence of augmentation, but which must be built up slowly to enhance tolerability. Two new dopamine agonists, Mirapex and Requip, demonstrate therapeutic benefits but are not efficacious enough to replace the tested agonists. While treatment of RLS has greatly improved over the history of the disorder, the search still continues for a single therapy that can effectively treat RLS patients over the long term without fear of augmentation and undesirable side effects.",
author = "Arthur Walters and Wayne Hening and Richard Allen",
year = "1999",
doi = "10.1017/S1092852900025293",
language = "English (US)",
volume = "4",
pages = "1--7",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "S2",

}

TY - JOUR

T1 - Current Treatment for Restless Legs Syndrome

AU - Walters, Arthur

AU - Hening, Wayne

AU - Allen, Richard

PY - 1999

Y1 - 1999

N2 - Medication treatment for restless legs syndrome (RLS) began with the opioids, which were first introduced as treatment in the 17th century and are still used today. Then came the benzodiazepines, the first “modern” treatment for RLS. Today, Sinemet and the dopamine agonists are first-line treatments—their efficacy make them the most commonly used medications. The benzodiazepines are effective for mild cases of RLS, but are not typically used as a monotherapy and often necessitate combination with the opioids or a dopamine agonist. The opioids can be used in a number of clinical settings, and studies are being conducted to test their efficacy as a long-term monotherapy for certain patients. The advent of dopamine agents, particularly Sinemet, has revolutionized RLS treatments. Studies show 90–100% initial efficacy. However, continued use of Sinemet can produce augmentation of a patient's symptoms. To combat augmentation a dopamine agonist like Permax is typically introduced, which has a much lower incidence of augmentation, but which must be built up slowly to enhance tolerability. Two new dopamine agonists, Mirapex and Requip, demonstrate therapeutic benefits but are not efficacious enough to replace the tested agonists. While treatment of RLS has greatly improved over the history of the disorder, the search still continues for a single therapy that can effectively treat RLS patients over the long term without fear of augmentation and undesirable side effects.

AB - Medication treatment for restless legs syndrome (RLS) began with the opioids, which were first introduced as treatment in the 17th century and are still used today. Then came the benzodiazepines, the first “modern” treatment for RLS. Today, Sinemet and the dopamine agonists are first-line treatments—their efficacy make them the most commonly used medications. The benzodiazepines are effective for mild cases of RLS, but are not typically used as a monotherapy and often necessitate combination with the opioids or a dopamine agonist. The opioids can be used in a number of clinical settings, and studies are being conducted to test their efficacy as a long-term monotherapy for certain patients. The advent of dopamine agents, particularly Sinemet, has revolutionized RLS treatments. Studies show 90–100% initial efficacy. However, continued use of Sinemet can produce augmentation of a patient's symptoms. To combat augmentation a dopamine agonist like Permax is typically introduced, which has a much lower incidence of augmentation, but which must be built up slowly to enhance tolerability. Two new dopamine agonists, Mirapex and Requip, demonstrate therapeutic benefits but are not efficacious enough to replace the tested agonists. While treatment of RLS has greatly improved over the history of the disorder, the search still continues for a single therapy that can effectively treat RLS patients over the long term without fear of augmentation and undesirable side effects.

UR - http://www.scopus.com/inward/record.url?scp=85011436309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011436309&partnerID=8YFLogxK

U2 - 10.1017/S1092852900025293

DO - 10.1017/S1092852900025293

M3 - Article

AN - SCOPUS:85011436309

VL - 4

SP - 1

EP - 7

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - S2

ER -